Overdosage has been reported with XYZAL.

Symptoms of overdose may include drowsiness in adults and initially agitation and restlessness, followed by drowsiness in children. There is no known specific antidote to XYZAL. Should overdose occur, symptomatic or supportive treatment is recommended. XYZAL is not effectively removed by dialysis, and dialysis will be ineffective unless a dialyzable agent has been concomitantly ingested.

The acute maximal non-lethal oral dose of levocetirizine was 240 mg/kg in mice (approximately 200 times the maximum recommended daily oral dose in adults and approximately 230 times the maximum recommended daily oral dose in children) on a mg/m² basis. In rats the maximal non- lethal oral dose was 240 mg/kg (approximately 390 times the maximum recommended daily oral dose in adults and approximately 460 times the maximum recommended daily oral dose in children on a mg/m² basis).

The use of XYZAL is contraindicated in:

• Patients with known hypersensitivity to levocetirizine or any of the ingredients of XYZAL, or to cetirizine. Observed reactions range from urticaria to anaphylaxis [see ADVERSE REACTIONS].
• Patients with end-stage renal disease (CL_CR < 10 mL/min) and patients undergoing hemodialysis.
• Pediatric patients 6 to 11 years of age with impaired renal function [see Use in Specific Populations].

Bookmark this page: